Clal Biotechnology Industries
Presencia
AAR Consortium posee 46 subsidiarias incluyendo A1, ABH Holdings y Access Industries.
Ellos se encuentran en:
Ejecutivos
Ver el organigrama con sus 12 ejecutivos principales
Biografías más buscadas en Clal Biotechnology Industries
Crear su alerta
para seguir los movimientos de los ejecutivos en Clal Biotechnology Industries.
Biotecnología
AAR Consortium tiene 2.273 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnología
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (publicado el 16 de abril de 2024).
- Nurix Therapeutics acaba de anunciar una recaudación de fondos de 175 millones de dólares. (publicado el 13 de abril de 2024).
- Nuvation Bio has announced the acquisition of AnHeart (publicado el 12 de abril de 2024).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Clal Biotechnology Industries
- MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma | MediWound
- MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers | MediWound
- Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 – Investors – Gamida Cell Ltd.
- BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization | BioLineRx
- BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer | BioLineRx
- BioLineRx Announces Preliminary Phase 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Second Line Patients With Metastatic Pancreatic Cancer | BioLineRx
- BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer | BioLineRx
- BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition | BioLineRx
- Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in Non-Alcoholic Steatohepatitis (NASH)
- Efficacy and safety of mij821 in patients with treatment-resistant depression: Results from a randomized, placebo-controlled, proof-of-concept study | European Psychiatry | Cambridge Core
- View more press releases Close
Redes sociales sobre Clal Biotechnology Industries
- Clal Biotechnology Industries en Wikipedia, Google News y Yahoo Finance
- Clal Biotechnology Industries en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Avi Fischer 
Llame a Clal Biotechnology Industries al +972 ...
